Skip to content
Lipella Pharmaceuticals, Inc. Logo
  • HOME
  • ABOUT
  • TRIALS
    • Hemorrhagic Cystitis Clinical Trial
    • Radiation Cystitis Patient Registry
  • MANAGEMENT
  • PUBLICATIONS
    • Press Releases
  • INVESTORS
    • Corporate Overview
    • SEC Filings
    • Press Releases
    • Stock Quote
    • Events & Presentations
    • Corporate Governance
    • FAQ’s
    • Investor Relations Contact
  • Sliding Bar Toggle
  • Radition Cystitis Registry
Stock QuoteLipella Pharmaceuticals, Inc2023-02-07T19:23:54+00:00

Investors

  • Corporate Overview
  • SEC Filings
  • Press Releases
  • Stock Quote
  • Events & Presentations
  • Corporate Governance
  • FAQ’s
  • Investor Relations Contact

Lipella Pharmaceuticals Inc. Code of Ethics

CHARTERS:

Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Charter

Lipella Pharmaceuticals Inc.
7800 Susquehanna St, Suite 505
Pittsburgh, PA 15208
USA

2023  © Copyright - Lipella Pharmaceuticals, Inc.

Close Sliding Bar Area

Recent Posts

  • Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
  • Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
  • Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry
  • Lipella Pharmaceuticals Announces Successful Completion of Pre-IND Type B FDA Meeting Regarding Oral Lichen Planus Drug Candidate
  • Bladder Health Foundation Launches Patient Registry for Survivors of Pelvic Radiation Therapy

Lipella Pharmaceuticals, Inc.

Phone: 412-894-1853

Email: Get In Touch Via Email

Reach Out

Investors

  • Corporate Overview
  • SEC Filings
  • Press Releases
  • Stock Quote
  • Events & Presentations
  • Corporate Governance
  • FAQ’s
  • Investor Relations Contact
Page load link
Go to Top